Kramer Robin 4

What happened
Robin Kramer, Chief Financial Officer of Biogen (BIIB), received a grant of 8,450 restricted stock units (RSUs) on February 13, 2026. The award was recorded as a derivative acquisition at $0.00 per unit (no cash outlay). These RSUs do not represent immediately vested shares and will convert into common stock only as they vest.

Key details

• Transaction type: Award/Grant (derivative) of 8,450 RSUs on 2026-02-13. Report filed 2026-02-17.
• Price: $0.00 per unit (no purchase price). Total immediate cash value not stated in the filing.
• Vesting: RSUs vest in three equal yearly installments beginning on the first anniversary of the grant (see footnote).
• Shares owned after transaction: Not specified in this filing.
• Filing timeliness: Form 4 filed four days after the grant date; insiders must generally file within two business days — check the official filing for any late-filing notation.

Context
RSU grants are a common form of executive compensation and represent potential future common shares upon vesting; they do not indicate an immediate buy or sell of stock. Because vesting is spread over three years, the economic benefit is realized over time and may be subject to standard tax withholding when shares vest. This type of grant is routine corporate compensation rather than an open-market purchase or sale.